Genetic Testing, But No Drugs, On Revised List Of Potential Medicare NCD Topics
This article was originally published in The Pink Sheet Daily
CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.
You may also be interested in...
Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.
CMS’ proposed update to its Medicare Part B National Coverage Determination would provide payment for aprepitant when used for patients receiving moderately emetogenic chemotherapy, not just highly emetogenic treatments.
CMS officials Jonathan Blum, Louis Jacques and Tamara Jensen addressed a number of Medicare Part B-related topics of interest to the biopharmaceutical industry at the FDA/CMS Summit, including reimbursement for high-priced oncology drugs, coverage with evidence development and national coverage determinations.